Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-22

FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Alembic Pharmaceuticals Limited)

View source ↗

Summary

FDA approved a supplemental application for rivastigmine tartrate by Alembic Pharmaceuticals Limited, authorizing a generic rivastigmine tartrate product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rivastigmine tartrate (rivastigmine tartrate)

Snippet

SUPPL AP for RIVASTIGMINE TARTRATE (RIVASTIGMINE TARTRATE)